Test of Nuclear Medicine- Oncology 5th Year PMU

Descrição

Test of Nuclear Medicine- Oncology 5th Year PMU
Med Student
Quiz por Med Student , atualizado more than 1 year ago
Med Student
Criado por Med Student mais de 4 anos atrás
2030
10

Resumo de Recurso

Questão 1

Questão
Which are the main goals of nuclear oncology
Responda
  • Imaging of the functional activity and the degree of proliferation of the tumor
  • The degree of malignant tumor spread: lymphogenic and haematogenic
  • Imaging and quantitative assessment of the effect from chemo- and hormone-therapy
  • All answers are correct

Questão 2

Questão
The scanning systems used in nuclear medicine are based on the principle of
Responda
  • Emission of Gamma-rays from the scanning system
  • Transition of Roentgen-rays through the patient's body
  • Detection of Gamma-rays or positron emission (pairs of annihilation Gamma-rays) emitted from the studied object
  • All answers are correct

Questão 3

Questão
Which methods of nuclear medicine are used for diagnosis of malignant tumours
Responda
  • PET/CT
  • Gamma camera scintigraphy
  • Radioimmunoassay of tumour markers
  • All answers are correct

Questão 4

Questão
Nuclear medicine diagnosis provides
Responda
  • Metabolic imaging
  • Quantitative assessment of physiological processes in the human body
  • Targeted planning of radiotherapy
  • All answers are correct

Questão 5

Questão
Nuclear medicine applies
Responda
  • Unsealed radioactive sources for medical diagnosis
  • Unsealed radioactive sources for radiotherapy
  • Sealed radioactive sources for medical diagnosis and therapy
  • Correct answers- a) and b)

Questão 6

Questão
PET/CT is a multimodality system combining
Responda
  • PET scanner with low-dose CT for improvement of the quality and precise localization of the functional image
  • PET scanner with possibility for additional targeted diagnostic contrast CT
  • Acquisition and fusion of functional and structural-anatomic images
  • All answers are correct

Questão 7

Questão
CT and PET scans demonstrate different aspects of disease indicating regions with
Responda
  • Altered metabolism (PET) and areas of structural change (CT)
  • Altered metabolism (CT) and areas of structural change (PET)
  • Altered metabolism (PET) and areas of structural change (PET)
  • Altered metabolism (CT) and areas of structural change (CT)

Questão 8

Questão
Which of the following diagnostic methods belong to modern Nuclear medicine
Responda
  • PET/CT
  • SPECT/CT
  • PET/MRI
  • All answers are correct

Questão 9

Questão
Which radionuclides are used for metabolic brachytherapy
Responda
  • High-energy γ (Gamma) emitters
  • β- (Beta)-emitters
  • β- (Beta) and γ (Gamma)-emitters
  • Correct answers — b) and c)

Questão 10

Questão
Nuclear medicine methods are used for
Responda
  • Diagnosis of benign and malignant diseases
  • Treatment of benign diseases
  • Treatment of malignant diseases
  • All answers are correct

Questão 11

Questão
PET /CT imaging has demonstrated significant application in the following clinical areas EXCEPT
Responda
  • Oncology
  • Cardiology
  • Pulmonology
  • Neurology

Questão 12

Questão
Which radiopharmaceuticals are used for tumor-specific imaging
Responda
  • 131 I- NaI
  • III In-Octreoscan
  • 99m Tc-Tetrofosmin
  • All answers are correct

Questão 13

Questão
Malignant tumors present on scintigraphy with tumor-specific radiopharmaceuticals as
Responda
  • Zones of increased uptake of the radiopharmaceuticals
  • Zones of decreased uptake of the radiopharmaceuticals
  • Zones of absent uptake of the radiopharmaceuticals
  • Zones of normal uptake of the radiopharmaceuticals

Questão 14

Questão
The most frequently used radiopharmaceutical for PET/CT imaging is
Responda
  • 18F-FDG
  • 99mTc-Pertechnetate
  • 131-Iodine — Nal
  • No correct answer

Questão 15

Questão
The PET scanner is detector of
Responda
  • Alfa-particles
  • Beta-particles
  • Pairs of annihilation Gamma rays
  • All answers are correct

Questão 16

Questão
Bone scintigraphy is
Responda
  • Highly specific diagnostic method
  • Highly sensitive diagnostic method
  • Highly sensitive and highly specific diagnostic method
  • Non-sensitive and non-specific diagnostic method

Questão 17

Questão
The main indication for bone scintigraphy is
Responda
  • Inflammatory bore disorders
  • Early detection of bone metastases
  • Benign bone tumors
  • Degenerative joint disorders

Questão 18

Questão
Metabolic brachytherapy with Metastron (89 Stroncium) is applied in patients with
Responda
  • Bone metastases
  • Pulmonary metastases
  • Brain metastases
  • Liver metastases

Questão 19

Questão
Contraindication for metabolic brachytherapy in patients with metastatic bone disease is
Responda
  • Advanced stage of the disease
  • Considerable myelo-depression
  • Inflammatory conditions
  • All answers are correct

Questão 20

Questão
Differentiated Thyroid cancer after total thyroidectomy and manifested distant haematogenic metastases is treated successfully with
Responda
  • Operation
  • Radioiodine metabolic brachytherapy
  • Chemotherapy
  • Electron therapy

Questão 21

Questão
Which of the following statements describing 18-F FDG PET imaging in thyroid carcinoma is FALSE
Responda
  • 18-F FDG PET can be negative in well differentiated types
  • 18-F FDG PET negative lesions are more likely to be resistant to 1-131 treatment
  • 18-F FDG uptake is proportional to Iodine uptake
  • 18-F FDG PET may not be accurate in patient with Tg levels below 2 ng/ dL

Questão 22

Questão
The most specific method for follow-up after treatment of Differentiated thyroid cancer is
Responda
  • Roentgenography
  • Thyroglobulin
  • Whole-body scintigraphy with 131-Iodine
  • Correct answers — b) and c)

Questão 23

Questão
A Thyroid cancer presents on the conventional scintigram with 99mTc as
Responda
  • Hot nodule
  • Warm nodule
  • Cold nodule
  • All answers are correct

Questão 24

Questão
Which histologic types of Thyroid cancer COULD NOT be treated with 131-Iodine metabolic brachytherapy
Responda
  • Papillary
  • Follicular
  • Medullary and anaplastic
  • Correct answers — a) and b)

Questão 25

Questão
An oncology patient referred for PET/CT should fast prior to the appointment for at least
Responda
  • 12h
  • 8h
  • 4h
  • 2h

Questão 26

Questão
The recommended time interval for PET/CT. imaging after biopsy is
Responda
  • 1 week
  • 2-4 weeks
  • 2-6 months
  • more than 6 months

Questão 27

Questão
In order to avoid false-positive results, FDG PET/ CT scans should be performed
Responda
  • 1-2 weeks after the last cycle of chemotherapy
  • 2-4 weeks after the last cycle of chemotherapy
  • 4-6 weeks after the last cycle of chemotherapy
  • 6-8 weeks after the last cycle of chemotherapy

Questão 28

Questão
False-negative PET/CT scans in lung cancer imaging occur predominantly because of
Responda
  • Lesions are too big to be evaluated by PET
  • Lesions are too superficial to be evaluated by PET
  • Lesions are too small to be evaluated by PET
  • Lesions are too deep to be evaluated by PET

Questão 29

Questão
F-18 FDG PET/CT is considered as a superior modality, compared with CT for evaluating post-treatment response in lymphoma patients because of
Responda
  • The ability to provide anatomical information
  • The ability to differentiate viable tumour from fibrosis
  • Higher resolution
  • Shorter imaging

Questão 30

Questão
A breast-feeding patient referred for PET/CT imaging should
Responda
  • Discontinue breast-feeding 12 h before injection of radiotracer
  • Discontinue breast-feeding 6 h before injection of radiotracer
  • Discontinue breast-feeding for at least 6 h after injection of radiotracer
  • Discontinue breast-feeding for at least 12 h after injection of radiotracer

Questão 31

Questão
A PET quantifier, calculated as the tracer activity concentration within a volume of interest divided by the injected dose per unit body weight is
Responda
  • Fractional uptake value
  • Standardized upload value
  • Standardized uptake value
  • Fractionai upload value

Questão 32

Questão
The Standardized Uptake Value (SUV) is
Responda
  • The measured activity divided by the body mass
  • The amount of tracer needed for a particular body weight
  • The measured activity normalized for body weight and inject dose
  • The measured activity within a particular organ divided by the sampled volume

Questão 33

Questão
For optimal patient care and interpretation of FDG PET/CT images, the following information from the patient should be obtained
Responda
  • Breast-feeding info
  • Recent surgery info
  • Use of medication info
  • All answers are correct

Questão 34

Questão
FDG PET/CT provides beneficial information in all of the following areas of lymphoma evaluation EXCEPT
Responda
  • Diagnosis
  • Response to therapy
  • Recurrence detection
  • Staging

Questão 35

Questão
Which of the following statements correctly explains the influence of FDG PET/CT imaging on staging in patients with Hodgkin's lymphoma
Responda
  • Upstaging of approximately 15-25 % of patients
  • Down-staging in a small minority of patients
  • Upstaging in a small minority of patients
  • Down-staging of approximately 15-25 % of patients

Questão 36

Questão
All of the following are well-established indications for FDG PET/CT imaging in patients with recurrent colorectal carcinoma EXCEPT
Responda
  • Falling CEA levels in the absence of a known source
  • Staging recurrent colorectal carcinoma
  • Preoperative staging
  • Equivocal lesion on conventional imaging

Questão 37

Questão
When monitoring response to treatment with FDG PET/CT Imaging is essential to obtain
Responda
  • Baseline FDG PET/CT scan
  • Interim FDG PET/CT scan
  • FDG PET/CT scan on the last day of therapy
  • FDG PET/CT scan two days after therapy

Questão 38

Questão
FDG uptake by cancer cells tends to decline as
Responda
  • Blood glucose and insulin levels decrease
  • Blood glucose level decrease and insulin levels increase
  • Blood glucose and insulin levels increase
  • Blood glucose level increase and insulin levels decrease

Questão 39

Questão
All of the following statements describe the usefulness of FDG PET/CT imaging in malignant pleural mesothelioma (MPM) EXCEPT
Responda
  • FDG PET/CT reduces the number of futile surgical procedures
  • FDG PET/CT imaging is useful for guiding needle biopsy
  • FDG PET/CT increases the accuracy of overall MPM staging
  • High levels of FDG uptake are associated with a favourable prognosis

Questão 40

Questão
The intensity of FDG uptake in the majority of mesotheliomas
Responda
  • Ranges from absent to low
  • Ranges from low to moderate
  • Ranges from moderate to high
  • Is always high

Questão 41

Questão
Selected tumours with low FDG uptake include all of the following EXCEPT
Responda
  • Prostate carcinoma
  • Iodine-avid differentiated thyroid carcinoma
  • Metastatic liver carcinoma
  • Hepatocellular carcinoma

Questão 42

Questão
All of the following statements correctly describe the postsurgical 18-F FDG uptake at the intervention site EXCEPT
Responda
  • Postsurgical 18-F FDG uptake is mainly diffuse
  • Postsurgical 18-F FDG uptake corresponds to the site of surgery
  • Postsurgical 18-F FDG uptake increases in intensity with time
  • Postsurgical 18-F FDG uptake in size with time

Questão 43

Questão
18-F FDG PET/CT should be performed on patients previously treated for differentiated thyroid cancer when the finding of 131-I whole body scintigraphy are negative and
Responda
  • The thyroglobuline (Tg) levels are more than 10 ng/ mL
  • The thyroglobuline (Tg) levels are less than 10 ng/ mL
  • The TSH levels are more than 30 mIU/L
  • The TSH levels are less than 30 mIU/ L

Questão 44

Questão
FDG PET/CT findings in anaplastic thyroid cancer can be described by all of the following EXCEPT
Responda
  • FDG PET/CT defines the local extent of disease and the presence of metastases
  • A positive PET/CT scan after therapy is linked with longer survival
  • FDG PET/CT have an impact on patients' management
  • Intense FDG uptake and volume are prognostic for a bad outcome

Questão 45

Questão
FDG PET/CT used in patients with suspected and residual/ recurrent gliomas is limited by
Responda
  • The low 18-F FDG uptake in normal brain tissue
  • The high 18-F FDG uptake in normal brain tissue
  • The low 18-F FDG uptake in tumour tissue
  • The high 18-F FDG uptake in tumour tissue

Questão 46

Questão
18-F FDG PET imaging is NOT indicated for initial staging of
Responda
  • Breast cancer
  • Hodgkin's lymphoma
  • Prostate cancer
  • Lung cancer

Questão 47

Questão
Which of the following statements describing 18-F FDG PET in the diagnostic work-up of patients with melanoma is FALSE
Responda
  • FDG PET is a standard modality in evaluation of recurrent melanoma
  • Melanin content influences lesion detectability by FDG PET
  • FDG PET is most valuable in stage III disease
  • FDG PET is more accurate for systemic staging than regional staging

Questão 48

Questão
Ovarian uptake of 18-F FDG in a postmenopausal patient indicates
Responda
  • A normal finding
  • Malignancy
  • Pregnancy
  • Benign ovarian cyst

Questão 49

Questão
F-18 FDG focal uptake seen 6 months after completion of radiation therapy should be considered as
Responda
  • Tumour recurrence
  • Normal finding
  • Radiation necrosis
  • Radiation pneumonitis

Questão 50

Questão
According to the PERCIST (PET Response Criteria in Solid Tumours) criteria for treatment response evaluation, the changes in SUVs should be assessed as
Responda
  • Percentage change in the same lesion
  • Percentage change in the “hottest” lesion
  • Value change in the same lesion
  • Value change in the “hottest” lesion

Semelhante

Anaesthesiology MCQs 1- 5th Year PMU
Med Student
Gastro-Intestinal Disorders- Clinical Pharmacology 5th Year PMU
Med Student
Infection Disorders- Clinical Pharmacology 5th Year PMU
Med Student
Oncology Final MCQs 1- 5th Year PMU
Med Student
Cell Physiology and General Physiology of Excitable Tissues- Physiology PMU 2nd Year
Med Student
General Physiology of the Nervous System Physiology PMU 2nd Year
Med Student
Blood MCQs Physiology PMU 2nd Year
Med Student
General Pathoanatomy Final MCQs (111-200)- 3rd Year- PMU
Med Student
General Pathoanatomy Final MCQs (401-519)- 3rd Year- PMU
Med Student
Microbiology MCQs 3rd Year Final- PMU
Med Student
Muscles- Physiology MCQs PMU- 2nd Year
Med Student